Explore WARF Inventions and Patents
WARF’s portfolio of more than 1,600 patented technologies covers a wide range of categories, including analytical instrumentation, pharmaceuticals, food products, agriculture, research tools, medical devices, pluripotent stem cells, clean technology, information technology and semiconductors.
Information summaries, which describe each technology and its applications, benefits, inventors and patent status, can be downloaded, printed and shared by clicking on the technology category links to the left on this page.
Visit our subscription center to sign up for our monthly email updates and learn when new WARF technologies become available for licensing.
The α/β-peptide mimics (or foldamers) can be tailored to target a variety of different proteins and protein-protein interactions. Given their small size (39 amino acids) relative to full-length Z-domains (59 amino acids), the new peptide mimics are easier to synthesize and modify.
Once the hydrogel array is formed, each of the spots can be exposed to different soluble factors without risk of diffusion.
The new amphiphiles, called CAO, DCAO and LCAO, are effective in challenging biochemical systems, such as extraction of delicate photosynthetic superassemblies from native lipid bilayers.
As compared to conventional lipid-based delivery systems, this formulation provides enhanced performance. When injected intravenously, it can rapidly and efficiently deliver high concentrations of fluorinated volatile anesthetics to specific active sites on ion channels and neurotransmitter receptors.
The film is made of random copolymer chains having crosslinkable functional groups. The film can be coated on a BCP substrate and then selectively removed.
Treating X-Linked Hypophosphatemia (XLH), Bone Deformity and Other Renal Phosphate Wasting Disorders
Administered alone or with other pharmaceutical agents, the arginine peptides work by enhancing FGF-23 degradation into inactive fragments and suppressing FGF-23 production. The resultant normalized levels of FGF-23 and other proteins completely rescue the HYP phenotype, including the abnormalities in the serum phosphate and bone mineralization.